Skip to main content
Premium Trial:

Request an Annual Quote

Mammoth Biosciences: Peter Nell, Ted Tisch

Mammoth Biosciences has appointed Peter Nell as chief business officer and head of therapeutics, and has named Ted Tisch chief operations officer.

Nell has previously served in various positions at Casebia Therapeutics and Bayer HealthCare. In his new role at Mammoth, he will scale the company's CRISPR offerings. Nell is a chemist by training, and is listed as co-inventor on more than 45 patents, and author or co-author of several scientific publications and book contributions in the biomedical field. 

Tisch joins Mammoth after four years at Synthego, where he established the product development, manufacturing operations, and commercial program for two CRISPR-based product lines. He previously served as vice president and general manager for Bio-Rad Laboratories' protein function division.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.